Synt:em Overview

  • Founded
  • 1995

Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Synt:em General Information

Description

Developer of drugs for the treatment of central nervous system (CNS) disorders. The company is a biopharmaceutical business focused on the discovery and development of new drug candidates for CNS diseases. The company re-engineers therapeutic molecules using peptides, as a means of delivering them to the brain.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Acquirer
CLL Pharma
Primary Office
  • Parc Scientifique
  • Georges Besse
  • 30035 Nimes
  • France
+33 04 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synt:em Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Jan-2005 000.00 Completed Generating Revenue
8. Merger/Acquisition 03-Nov-2004 000.00 000.00 Cancelled
7. Later Stage VC 09-Jan-2002 00.00 000.00 Completed Generating Revenue
6. Later Stage VC 07-Mar-2001 000.00 000.00 Completed Generating Revenue
5. Early Stage VC 17-Nov-1999 00.000 Completed Startup
4. Early Stage VC 07-Jan-1998 00.00 00.000 Completed Startup
3. Early Stage VC 01-Dec-1997 00.00 00.000 Completed Startup
2. Early Stage VC 01-Jun-1997 $347K $810K Completed Startup
1. Early Stage VC $462K $462K Completed Startup
To view Synt:em’s complete valuation and funding history, request access »

Synt:em Patents

  • 108

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Synt:em Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2005210063-A1 Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation Inactive 02-Feb-2004 00000000000
CA-2554822-A1 Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation Inactive 02-Feb-2004 00000000000
EP-1711521-A1 Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation Inactive 02-Feb-2004 00000000000
FR-2865736-A1 Inhibitors of angiogenesis, compositions containing same and use thereof for the treatment of diseases associated with deregulation of angiogenesis Active 02-Feb-2004 00000000000 0
FR-2865736-B1 Inhibitors of angiogenesis, compositions containing same and use thereof for the treatment of diseases associated with deregulation of angiogenesis Inactive 02-Feb-2004 C07K14/4703
To view Synt:em’s complete patent history, request access »

Synt:em Executive Team (1)

Name Title Board Seat Contact Info
Michel Kaczorek Ph.D Chief Executive Officer & Founder
To view Synt:em’s complete executive team members history, request access »

Synt:em Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Banexi Ventures Partners Venture Capital Minority 000 0000 000000 0
BankInvest Group Asset Manager Minority 000 0000 000000 0
Lombard Odier Investment Managers Asset Manager Minority 000 0000 000000 0
Rendex Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial